Additive Anti-inflammatory Action for Critically Ill Patients With Cardiovascular Surgery (Xuebijing) IV
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
XueBiJing, a Chinese herbal derived therapeutic, has been approved to treat severe infections
(sepsis) in critically ill patients (China Food and Drug Administration; Beijing, China,
Number Z20040033). Cardiopulmonary bypass (CPB) will produce large amounts of inflammatory
mediators and oxygen free radicals, which causes the lipid peroxidation damage and
mononuclear cell migration, thus aggravating organ inflammation and damage. Therefore,
exploring new methods to prevent and alleviate organ injury caused by CPB is an important
topi in clinical practice. However, little knowledge is regarding the effect of Xuebijing
injection on CPB-related organ injury. To answer these questions, the authors conducted this
randomized trial to compare XueBiJing with placebo in critically ill patients with
cardiovascular surgery.